Pre-Submission Facility Correspondence (PFC) Support for ANDA Submissions

Pre-Submission Facility Correspondence (PFC), sometimes called pre-facility correspondence, is an important part of ANDA planning under the Generic Drug User Fee Amendments (GDUFA III). MASUU Global supports pharmaceutical companies in preparing and managing PFC so facility information reaches FDA in an organized and timely manner.

What Is Pre-Submission Facility Correspondence (PFC)?

PFC involves providing FDA with facility-related information before an ANDA is submitted, as outlined under the GDUFA III reauthorization. It helps FDA understand the facilities involved in manufacturing and testing the proposed product, which supports facility assessment and inspection planning during the review.

Why PFC Matters in ANDA Planning

  • Supports early alignment between facility information and ANDA submission plans
  • Helps reduce avoidable facility-related questions during review
  • Encourages accurate, consistent facility details across submission documents
  • Supports compliance with GDUFA III expectations

Key Activities in PFC Support

Facility Information Review

We review facility details, roles, and responsibilities so information is complete and consistent before correspondence is prepared.

PFC Preparation and Submission

Our team prepares clear correspondence aligned with FDA expectations and supports submission according to your project timeline.

ANDA Timeline Coordination

We coordinate PFC activities with ANDA development milestones to keep regulatory planning practical and on track.

MASUU Global’s Approach and Expertise

MASUU Global follows a structured, compliance-focused approach to generic drug regulatory affairs. We review each project individually, confirm current GDUFA III requirements, and communicate expectations clearly with your team. Our focus is accurate documentation and dependable coordination, so you can approach ANDA submission with confidence. We keep communication clear and timely throughout, so your team always knows where each activity stands. Our reviewers check every document for accuracy and consistency before it reaches you, which supports dependable regulatory outcomes.

Benefits of PFC Support from MASUU Global

  • Organized and accurate facility information
  • Better alignment between facility planning and ANDA submission
  • Clear communication with internal and external stakeholders
  • Practical regulatory guidance throughout the process

Frequently Asked Questions

PFC is correspondence that provides FDA with facility-related information before an ANDA is submitted, as described under the GDUFA III reauthorization. It helps FDA understand the manufacturing and testing sites involved in a proposed generic drug product. Applicants should review current GDUFA III program requirements to confirm how PFC applies to their application.

PFC gives FDA advance visibility of the facilities linked to a planned ANDA, which can support facility assessment and inspection planning. Providing accurate information early helps reduce avoidable questions later in the review process. It also encourages applicants to confirm facility readiness and consistency across submission documents before filing the application.

The ANDA applicant is generally responsible for ensuring that PFC is submitted, although facility information is often gathered from manufacturing partners, contract sites, and testing laboratories. Clear internal ownership matters because several teams usually contribute data. MASUU Global can help coordinate inputs and prepare correspondence that reflects accurate, consistent facility details.

PFC generally focuses on facility-related details for sites involved in manufacturing and testing the proposed product, such as facility identification, site roles, and related contact information. Exact content depends on current FDA instructions and the specific application. Applicants should confirm requirements against current GDUFA III guidance before preparing the correspondence.

PFC should be planned early, before the ANDA submission, so facility information is ready when it is needed. Timing and any eligibility conditions are defined by the GDUFA III program and current FDA guidance. Building PFC into the development schedule helps avoid last-minute gaps, especially when several external facilities are involved.

PFC provides FDA with early facility information that can inform how facilities are assessed during ANDA review, including possible inspection planning. It does not replace inspection readiness. Facilities should still maintain current good manufacturing practice compliance, keep records accurate, and be prepared to support any inspection or related regulatory request.

Common challenges include incomplete facility details, inconsistent site names or identifiers across documents, unclear responsibilities among contract partners, and tight development timelines. These issues can delay preparation or create avoidable questions. A structured checklist, early information gathering, and careful cross-checking against other submission documents help applicants prepare dependable correspondence. Early checks also save valuable preparation time.

Applicants should compare facility names, addresses, roles, and identifiers across PFC, ANDA modules, and supporting documents before submission. Using a single controlled source of facility information reduces transcription errors. Regular reviews are also useful when sites change, because outdated details can create inconsistencies that need correction later in the process.

If facility details change, applicants should assess the impact on the planned ANDA and follow current FDA instructions for updating information. Prompt internal review helps determine what needs correction and which documents are affected. Maintaining clear change records and communicating updates quickly supports accuracy and reduces avoidable regulatory delays. Regular follow-up with partner sites keeps everyone informed.

MASUU Global supports PFC through facility information review, correspondence preparation, submission support, and alignment with ANDA planning under GDUFA III. Our team organizes inputs, checks consistency, and communicates requirements clearly. Contact MASUU Global to discuss your project and develop a practical approach to facility-related regulatory activities. We aim to keep the process organized and predictable.

Book a Demo